Mouse IL-6 ELISA kit
- Known as:
- Mouse Interleukin-6 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- BEK1109
- Product Quantity:
- 96 T
- Category:
- Elisa Kits
- Supplier:
- Biospect
- Gene target:
- Mouse IL-6 ELISA kit
Related genes to: Mouse IL-6 ELISA kit
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Mouse IL-6 ELISA kit
Related articles to: Mouse IL-6 ELISA kit
- Warm needle acupuncture (WNA) can improve symptoms in knee osteoarthritis (KOA). However, the molecular changes linked to its effects remain unclear. - Source: PubMed
Publication date: 2026/09/22
Xu BoSu QinHan DapengYao JieDing HaoyuanWang JiqingHuang ZhengMi Yiqun - Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint destruction and systemic inflammation, with limited long-term efficacy and clinically important adverse effects of current treatments. Astragaloside IV (ASIV), the core active saponin component isolated from , has shown anti-inflammatory, immunomodulatory, and joint-protective potential in multiple inflammatory disease models, while its underlying mechanism in RA remains to be fully elucidated. - Source: PubMed
Publication date: 2026/09/22
Ma YaoGuo QianyuLiang MeieLi ZhenZhang Liyun - Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a highly heterogeneous syndrome rather than a single disease entity. Identifying biologically distinct endotypes is essential for early risk stratification and precision prevention. Immunosenescence-the age-related remodeling of the immune system-has been associated with COPD pathogenesis, but its heterogeneity remains poorly characterized. - Source: PubMed
Publication date: 2026/09/22
Wu BiyingYang MinHu XiaoyingKe WencaiChen QiudanLin Yong - Osteoporosis (OP) is a systemic metabolic disease associated with inflammation and apoptosis of osteoblasts. Ubiquitin-specific protease 18 (USP18) has been shown to participate in the progression of bone metabolic disorders; however, its role in osteoblast injury remains unclear. A rat OP model was established via bilateral ovariectomy (OVX). Pathological changes were observed using H&E and Masson staining, and Western blotting was used to detect the expression of related proteins. In vitro, an inflammatory injury model was constructed by inducing MC3T3-E1 mouse osteoblasts with 1 µg/mL LPS. CCK-8, EdU, flow cytometry, and Co-IP were utilized to validate the role of USP18 in osteoblast injury. OVX-treated rat femoral tissue samples exhibited severe inflammatory cell infiltration and bone damage. USP18 expression was significantly downregulated in OP rats and in LPS-stimulated osteoblasts. Overexpression of USP18 significantly increased cell viability and proliferation; upregulated the expression of osteogenesis-related protein markers (Runx2, ALP, and OCN); and reduced the levels of inflammatory factors (TNF-α and IL-6) and apoptotic proteins (Bax and cleaved caspase-3), thereby ameliorating LPS-induced osteoblast injury. Mechanistic studies revealed that USP18 binds to TAK1, removes K63-linked ubiquitination modifications on TAK1, and inhibits the activation of the p38/JNK-MAPK pathway. Notably, the MAPK activator anisomycin or TAK1 overexpression weakened the protective effects of USP18 on osteoblasts. USP18 inhibits MAPK pathway activation by deubiquitinating TAK1 and alleviates LPS-induced inflammation and apoptosis in osteoblasts. Furthermore, USP18 overexpression mitigates OP progression. - Source: PubMed
Publication date: 2026/09/25
Chen GuopingLiang JinlongCui YiWei JiahengXu Yongqing - Piperine has diverse pharmacological and bioenhancing activities, but poor aqueous solubility, variable exposure, interaction liability, and discontinuity across production, formulation, and clinical evaluation limit translation. This review integrates these frequently separated stages. - Source: PubMed
Publication date: 2026/09/21
Syailatussuraya Malfa SalsabillaMutakin MutakinAsman SalizaHasanah Aliya Nur